|
Estrogen/Progesterone receptor status
|
|
+/− vs +/+ (18.6%)
|
1.40
|
1.10, 1.79
|
2.51
|
1.20, 5.30
|
|
−/+ vs +/+ (4.1%)
|
1.00
|
0.62, 1.59
|
5.63
|
1.55, 20.46
|
|
−/− vs +/+ (15.6%)
|
2.14
|
1.70, 2.70
|
9.76
|
4.39, 21.75
|
|
Grade
|
|
moderately differentiated vs well differentiated (36.4%)
|
1.61
|
1.15, 2.27
|
3.12
|
0.99, 9.91
|
|
poorly differentiated vs well differentiated (48.5%)
|
1.90
|
1.36, 2.66
|
6.54
|
2.02, 21.18
|
|
Tumor size (≥ 2 cm vs < 2 cm) (20.5%)
|
1.64
|
1.33, 2.01
|
4.70
|
2.27, 9.75
|
|
Axillary nodal involvement (yes vs no) (30.0%)
|
1.54
|
1.26, 1.86
|
5.23
|
2.63, 10.42
|
|
Recent MHT use before diagnosis (yes vs no) (44.3%)
|
0.75
|
0.62, 0.92
| | |
|
Smoking status first follow-up after diagnosis
|
|
ex-smoker vs never smoker (36.9%)
|
1.20
|
1.00, 1.44
| | |
|
current smoker vs never smoker (6.5%)
|
1.55
|
1.16, 2.07
| | |
|
Year of diagnosis
|
|
1995–1999 vs 1990–1994 (28.9%)
|
0.90
|
0.72, 1.13
| | |
|
2000–2003 vs 1990–1994 (32.3%)
|
0.72
|
0.56,0.94
| | |
|
2004–2008 vs 1990–1994 (27.4%)
|
0.61
|
0.43, 0.89
| | |
|
Age at breast cancer diagnosis (year)
|
|
[50–60) vs < 50 (44.1%)
| | |
1.80
|
0.68, 4.79
|
|
[60–70) vs < 50 (38.0%)
| | |
4.50
|
1.29, 15.78
|
|
≥ 70 vs < 50 (9.5%)
| | |
9.08
|
1.89,43.69
|
|
Menopausal status at breast cancer diagnosis
|
|
postmenopausal woman - no use of MHT vs premenopausal woman (27.1%)
| | |
1.39
|
0.58, 3.32
|
|
postmenopausal woman-less than 5 years of cumulated MHT use vs premenopausal woman (29.3%)
| | |
0.79
|
0.32, 1.97
|
|
postmenopausal woman-more than 5 years of cumulated MHT use vs premenopausal woman (28.8%)
| | |
0.35
|
0.11, 1.10
|
|
θ
|
1.01 (σ = 0.05) p-value< 0.001
|
|
α
|
4.29 (σ = 0.77) p-value< 0.001
|
